Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic antibodies.

Bernd Groner1, Cord Hartmann, Winfried Wels

  • 1Georg Speyer Haus, Institute for Biomedical Research, Paul Ehrlich Str. 42, D-60596 Frankfurt/M, Germany. groner@em.uni-frankfurt.de

Current Molecular Medicine
|July 23, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.

Journal for immunotherapy of cancer·2021
Same author

The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.

Archives of toxicology·2018
Same author

Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition.

Molecular and cellular endocrinology·2017
Same author

Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine.

Journal of innate immunity·2016
Same author

Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.

Cancer research·2015
Same author

5-Lipoxygenase is a direct p53 target gene in humans.

Biochimica et biophysica acta·2015

Monoclonal antibodies are now effective cancer drugs, overcoming early production and targeting challenges. Researchers are using engineered antibodies to inhibit tumor growth and deliver toxins.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Monoclonal antibodies (mAbs) were initially envisioned as targeted therapies.
  • Early challenges included molecular complexity, immunogenicity, and target identification.
  • Advances in humanization and target discovery have enabled their clinical success.

Purpose of the Study:

  • To review the development and therapeutic applications of monoclonal antibodies in cancer treatment.
  • To highlight the mechanisms by which mAbs combat cancer.
  • To discuss the evolution of mAbs from simple antibodies to complex drug conjugates.

Main Methods:

  • Development of humanized monoclonal antibodies to reduce immunogenicity.
  • Identification of specific cell surface targets crucial for cancer progression.

Related Experiment Videos

  • Engineering of antibody derivatives, such as single-chain Fv fragments, for targeted drug delivery.

    • Main Results:

    • Monoclonal antibodies like bevacizumab inhibit tumor neovascularization by targeting VEGF.
    • Antibodies such as cetuximab and pertuzumab block EGF receptor signaling pathways.
    • Trastuzumab targets ErbB2, halting cell cycle progression and recruiting immune cells.
    • Recombinant toxins utilizing antibody fragments demonstrate potent anti-cancer activity.

    Conclusions:

    • Monoclonal antibodies have evolved into powerful cancer therapeutics.
    • Diverse mechanisms, including growth factor sequestration, receptor blockade, and immune cell recruitment, are employed.
    • Antibody engineering continues to expand therapeutic potential, including targeted toxin delivery.